Bipartisan policies in Congress meant to lower drug costs by targeting middlemen in the pharmaceutical supply chain are likely to run up against a fundamental issue: the three major pharmacy benefit ...

The conclusion of the longest government shutdown in history and rising political acrimony rightly receives a great deal of attention but this focus makes it easy to overlook areas where beneficial ...

Vertical integration and limited PBM competition can distort formulary placement incentives, enabling rebate-driven list price inflation while obscuring true net costs from employers, pharmacies, and ...

In a conversation hosted by DSN, EmpiRx Health CEO Danny Sanchez and EmpiRx Health President John Ridyard detailed how their mid-market PBM is gaining traction by putting pharmacists at the center of ...

If lawmakers want to make pharmaceuticals more affordable, they should look past populist policies like price controls that will only make matters worse and set their sights on reforming the Pharmacy ...